Immunogen

ImmunoGen’s drug Elahere offers hope for ovarian cancer patients
ImmunoGen’s drug Elahere offers hope for ovarian cancer patients
Clinical Trials Arena
Immunogen
Elahere
clinical trials
platinum-resistant ovarian cancer
ovarian cancer
Flag link:
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
Clinical Trials Arena
Immunogen
clinical trial
ovarian cancer
platinum-resistant ovarian cancer
Elahere
Flag link:
Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy
Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy
Fierce Biotech
Vertex Pharmaceuticals
Immunogen
gen editing
antibody-drug conjugate
exa-cel
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
FDA Action Alert: Spectrum, ImmunoGen, Scynexis and Y-mAbs
FDA Action Alert: Spectrum, ImmunoGen, Scynexis and Y-mAbs
BioSpace
FDA
Spectrum Pharmaceuticals
poziotinib
Immunogen
mirevtuximab soravtansine
Scynexis
Brexafemme
Y-mAbs
Omblastys
Flag link:
FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon
FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon
Endpoints
Immunogen
FDA
ovarian cancer
mirvetuximab soravtansine
Flag link:
ImmunoGen commercial chief to withdraw before drug launch
ImmunoGen commercial chief to withdraw before drug launch
Medical Marketing and Media
Immunogen
mirvetuximab soravtansine
ovarian cancer
Flag link:
After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024
After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024
Fierce Biotech
Immunogen
antibody drug conjugate
pivekimab sunirine
blood cancer
Flag link:
ADC Space Continues to Thrive with Four More Companies Linking Up
ADC Space Continues to Thrive with Four More Companies Linking Up
BioSpace
antibody-drug conjugate
Exelixis
Bioinvent
Oxford BioTherapeutics
Immunogen
Flag link:
Amid Waves of Biotech Layoffs, ADC Developers like ImmunoGen are Thriving
Amid Waves of Biotech Layoffs, ADC Developers like ImmunoGen are Thriving
BioSpace
layoffs
antibody-drug conjugate
Seagen
Immunogen
Flag link:
ImmunoGen Ovarian Cancer Drug Reaches BLA Milestone
ImmunoGen Ovarian Cancer Drug Reaches BLA Milestone
BioSpace
Immunogen
ovarian cancer
FDA
mirvetuximab soravtansine
Flag link:
Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing
Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing
Fierce Biotech
Immunogen
mirvetuximab soravtansine
ovarian cancer
clinical trials
antibody-drug conjugate
Flag link:
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end
Fierce Biotech
Eli Lilly
Immunogen
antibody-drug conjugate
Flag link:
ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial
ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial
Fierce Biotech
Immunogen
mirvetuximab soravtansine
ovarian cancer
FDA
antibody-drug conjugate
Flag link:
After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan
After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan
Endpoints
Immunogen
FDA
IMGN632
blastic plasmacytoid dendritic cell neoplasm
Flag link:
ImmunoGen cuts deep to eke out cash for mirvetuximab trial
ImmunoGen cuts deep to eke out cash for mirvetuximab trial
Fierce Biotech
Immunogen
R&D
layoffs
Flag link:
A delicate balancing act for Immunogen
A delicate balancing act for Immunogen
EP Vantage
Immunogen
mirvetuximab soravtansin
Jazz Pharmaceuticals
IMGN779
IMGN632
Flag link:
FDA tells ImmunoGen to run a second phase 3, sinking stock
FDA tells ImmunoGen to run a second phase 3, sinking stock
Fierce Biotech
Immunogen
mirevtuximab soravtansine
ovarian cancer
clinical trials
Flag link:
ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint
ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint
BioSpace
Immunogen
ovarian cancer
clinical trials
mirvetuximab soravtansine
Flag link:

Pages